A study of MCLA-158 in the treatment of colorectal cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs MCLA 158 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; First in man
- 04 Jan 2018 According to a Merus media release, company got an CTA approval to initiate this trial in Belgium first quarter of 2018. Also, company plans to file an IND for MCLA-158 with the U.S. FDA in the first quarter of 2018.
- 28 Apr 2017 According to a Merus media release, company expects to file a CTA for this trial by the end of 2017.
- 03 Jun 2016 New trial record